The difficulty of appraisal of streptokinase treatment of myocardial infarction.
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003325:Coronary Care Units; D005938:Glucocorticoids / Q000627:therapeutic use; D005947:Glucose / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007008:Hypokalemia / Q000188:drug therapy; D007328:Insulin / Q000627:therapeutic use; D008012:Lidocaine / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy*; D010417:Pentaerythritol Tetranitrate / Q000627:therapeutic use; D010919:Placebos; D011188:Potassium / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D012770:Shock, Cardiogenic / Q000517:prevention & control; D013300:Streptokinase / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D005938:Glucocorticoids; D007328:Insulin; D010919:Placebos; D010417:Pentaerythritol Tetranitrate; D006493:Heparin; D008012:Lidocaine; D011433:Propranolol; D013300:Streptokinase; D005947:Glucose; D011342:Procainamide; D011188:Potassium